USPSTF recommends prescriptions for increased risk brCA patients

USPSTF: Offer Breast CA Risk-Reducing Rx to High-Risk Patients
USPSTF: Offer Breast CA Risk-Reducing Rx to High-Risk Patients

(HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends that women at increased risk of breast cancer be prescribed tamoxifen or raloxifene for risk reduction, according to a final Recommendation Statement published online Sept. 24 in the Annals of Internal Medicine.

To update the 2002 USPSTF recommendations, researchers from the USPSTF reviewed evidence on the effectiveness, adverse effects, and subgroup variations of medication to reduce the risk of breast cancer. They specifically focused on the selective estrogen receptor modulators tamoxifen and raloxifene, and reviewed a meta-analysis of placebo-controlled trials to assess the benefits and harms of these medications.

Based on the findings, the researchers recommend that clinicians engage in shared, informed, decision making for women aged 35 years or older, at risk of breast cancer. For women with low risk for adverse medication effects who are at increased risk of breast cancer, clinicians should offer to prescribe risk-reducing medications (Grade B recommendation). For women who are not at increased risk of breast cancer, the USPSTF recommends against routine use of medications such as tamoxifen and raloxifene (Grade D recommendation).

"While these medications have some significant side effects, it is important that clinicians and women at high risk for breast cancer be aware of the options these drugs offer," USPSTF member Wanda Nicholson, M.D., M.P.H., M.B.A., said in a statement.

Full Text

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs